Abstract: Dermatitis herpetiformis and linear IgA bullous dermatosis are autoimmune diseases that present with pruritic urticarial papules and plaques, with formation of vesicles and blisters of subepidermal location, mediated by IgA antibodies. Mucosal lesions are present only in linear IgA bullous dermatosis. The elaboration of this consensus consisted of a brief presentation of the different aspects of these dermatoses and, above all, of an updated literature review on the various therapeutic options that were discussed and compared with the authors' experience, aiming at the treatment orientation of these diseases in Brazil. Dermatitis herpetiformis is a cutaneous manifestation of celiac disease, and can be controlled with a gluten-free diet and dapsone. On the other hand, linear IgA bullous dermatosis arises spontaneously or is triggered by drugs, and can be controlled with dapsone, but often requires the association of systemic corticosteroids and eventually immunosuppressants. 
INTRODUCTION
Dermatitis herpetiformis (DH), also known as Duhring-Brocq disease, is a chronic autoimmune dermatosis that is caused by a hypersensitivity to gluten, usually manifesting as papulovesicular and eroded/crusted lesions, with intense pruritus and burning, preferentially located on the elbows, knees, and buttocks. Presenting as a cutaneous manifestation of celiac disease (CD), general and gastrointestinal symptoms are rare, although most patients show small bowel villous atrophy. 1 A definitive diagnosis is made, based on the presence of granular IgA deposits on dermal papillae by direct immunofluorescence, the target antigen of which is the epidermal transglutaminase enzyme. The dermatological condition responds slowly to a gluten-free diet but undergoes prompt resolution with oral dapsone.
EPIDEMIOLOGY
There are no epidemiological studies on DH in Brazil, but it is considered an uncommon disease in this country, based on the experience of specialists. The prevalence is higher in Northern Europe, is the antigenic target of IgA deposits in the intestinal mucosa in CD, whereas epidermal transglutaminase (TG3) is targeted by IgA deposits on the skin in DH. Autoantibodies against TG2 from the gut then react with TG3 to form immunocomplexes, which deposit on the dermal papillae and trigger a local inflammatory process with neutrophil chemotaxis. Although there are several reports of a link to lymphomas, primarily the non-Hodgkin type, the relationship between DH and the development of lymphoma is a controversial subject. 8 An epidemiological study of 846 DH patients showed no increased mortality or greater risk of developing lymphomas and intestinal malignancies compared with the general population.
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CLINICAL FEATURES
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LABORATORY DIAGNOSIS
For the diagnosis, a lesion specimen, preferably an intact vesicle, should be collected for routine anatomopathological examination, and another sample of perilesional healthy skin should be analyzed by direct immunofluorescence (DIF).
Typical histopathological findings are a subepidermal vesicle with neutrophils in its interior, in addition to neutrophils that form microabscesses in the dermal papillae. These findings are not exclusive to DH and may be seen in other bullous dermatoses. 10, 11 It is important to note that the histopathological condition is usually non-specific in 35% to 40% of cases, presenting only as a perivascular lymphocytic infiltrate and minimal inflammation in the dermal papilla. 12 Conversely, DIF with granular IgA deposits at tips of dermal papillae is the gold standard test for DH diagnosis, which has a sensitivity of 90% to 95%. 13, 14 The detection of circulating autoantibodies completes the diagnosis of the disease, but it is unnecessary. Anti-TG3 antibodies are more sensitive and important in DH, but anti-TG2, antiendomysium, and antigliadin antibodies, which are more related to celiac disease, can be detected. Intestinal biopsy is not indicated in a patient with confirmed DH, because it is the cutaneous manifestation of celiac disease.
It is also unnecessary as a means to check patient adherence to the diet, which can be assessed easily by observation of skin lesions and serological tests.
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TREATMENT
1-Professionals involved
Depending on the patient's age and the presence of general and gastrointestinal symptoms, in addition to the dermatologist, intervention by an internist, pediatrician, gastroenterologist, nutritionist, and digestive endoscopist may be needed. 
3-Objectives
The initial goal comprises the control of dermatological symptoms, such as pruritus and burning, as well as the resolution of cutaneous lesions, which can be attained more quickly with medication. However, the improvement of digestive symptoms, when present, can only be achieved with diet, which is also important for long-term control of the dermatological condition. Intestinal involvement may affect the development of children who are affected by the disease, who should be evaluated using growth curves during follow-up. Emphasis should be placed on adherence to diet as a measure of intestinal disease control, even in asymptomatic patients, to prevent late complications of the disease. 
-Treatment plan a) Gluten-free diet
Both gastrointestinal, if present, and cutaneous manifestations respond to a gluten-free diet-the former after 3-6 months but the latter after 1-2 years. 15 Therefore, medications must be combined in the first years of treatment, even in patients with good adherence to diet.
Foods that are derived from wheat, rye, barley, and malt should be discarded, and pure oat consumption is allowed; however, most oat products on the market are contaminated with gluten.
Patients should be instructed to consult processed food labels closely for the presence of gluten in their composition and avoid eating foods with unknown ingredients. It is important to remind patients that many excipients, and food and pharmaceutical additives may contain gluten. 19 Because gastrointestinal symptoms are absent or mild in most cases and because the skin condition is controlled rapidly by medication, it becomes difficult to convince patients to adhere to a strict diet, considering its complexity, cost, and social limitations.
Hence, patients should be guided by a nutritionist and participate in support groups to acquire greater knowledge about the diet.
Supplementation with iron, folate, and vitamins D and B12 may be needed when their deficiencies are confirmed. Even patients who fail to eliminate but only reduce their gluten intake may gain some benefit, however without complete control of the cutaneous condition, depending on the medication. 20, 21 In addition to resolving cutaneous and gastrointestinal symptoms, a gluten-free diet improves malabsorption, allowing dose reduction and possibly discontinuation of medication and helping prevent the development of lymphomas by lowering persistent antigenic stimulation.
b) Dapsone
Dapsone is the drug of choice in DH, because it relieves pruritus in a few hours and resolves skin lesions in several days, but on halting this medication, the condition recurs in 24 to 48 hours. 18 However, it has no effect on intestinal disease or in reducing the risk of lymphoma. 8, 22 Dapsone has anti-inflammatory activity, inhibiting neutrophil chemotaxis, the release of leukotrienes and prostaglandins, and reducing tissue damage that is mediated by neutrophils and eosinophils. lesions in most cases. 15 The lowest dose that is required to maintain cutaneous disease in remission should be determined and then discontinued when the benefits from the diet are obtained, which usually occurs after 1-2 years. For children, a dosage of 1-2mg/kg/d is recommended. Laboratory tests, including glucose-6-phosphate dehydrogenase (G6PD), complete blood count, reticulocyte count, liver enzymes, bilirubin, creatinine, and urinalysis, should be performed prior to starting medication. They should be repeated every 2 weeks in the first 3 months of treatment and then every 3 months. 24 The main adverse effects of dapsone are dose-dependent hemolysis and methemoglobinemia; therefore, most patients usually tolerate it as long as the dose is adjusted individually. Greater caution should be placed on G6PD-deficient patients, in whom acute hemolytic anemia is usually more severe, requiring drug withdrawal. Due to its effect of preventing the oxidative stress that dapsone exerts on red blood cells, some groups advocate the use of vitamin E at a dosage of 800mg/d to minimize the risk of hemolytic anemia. 25 Methemoglobinemia is generally insidious but well tolerated at levels below 20% and should be suspected in the presence of cyanosis, dizziness, dyspnea, lethargy, and headache. 26 Cimetidine, at a dose of 400mg, 3-4 times a day, may reduce methemoglobinemia without interfering with the effects of dapsone on DH. 27 Other less common side effects include leukopenia, agranulocytosis, hypersensitivity reactions, peripheral neuropathy, nephrotic syndrome, and hepatic and pulmonary changes. 23 Agranulocytosis is rarer, which usually appears within the first 3 months of treatment. Hypersensitivity reactions to dapsone are more severe but rare, presenting as fever, rash, and lymphadenopathy, in addition to systemic involvement to varying degrees, and appear in approximately 1% of patients after 2-6 weeks of treatment.
Dapsone is contraindicated in patients with sulfa allergy, acute porphyrias, severe anemia, and severe cardiopulmonary disease. 28 Drug interactions are rare, but the concomitant use of trimethoprim or probenecid may raise plasma levels, increasing the hematological toxicity of dapsone. 8 With regard to the risk of use in pregnancy, it is classified as a category C drug (FDA) and therefore is not recommended during pregnancy or breastfeeding. However, the experience of its wide use in leprosy during pregnancy and the absence of deleterious effects in the mother and the fetus indicate that dapsone can be used safely in the gestational period. 
c) Alternative drugs
Sulfasalazine is the second-line drug when it is not possible to use dapsone due to its adverse effects and, less frequently, lack of response. Due to the variable absorption of sulfasalazine, its efficacy is less predictable compared with dapsone. 30 The usual recommended dosage is 1-2 g/d, but up to 4 g/d may be needed. 31 The most common adverse reactions are digestive, such as nausea, vomiting, and anorexia, which can be avoided with enteric-coated tablets. Hemolytic anemia, hypersensitivity reactions, proteinuria, and crystalluria are less common. Patients should be monitored with complete blood count and urinalysis before treatment, monthly in the first 3 months and every 6 months thereafter.
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Sporadic studies, based on case reports, have demonstrated the beneficial effects of other alternative drugs in DH, such as colchicine, cyclosporin, heparin, tetracycline, and nicotinamide. [33] [34] [35] [36] DH does not respond to systemic corticosteroids, and antihistamines have a limited effect on pruritus. 13 Potent topical corticosteroids may provide temporary relief of itching but are only allowed in the acute phase of the disease, until benefits of systemic treatment are obtained. 30 In refractory cases, immunosuppressants, such as methotrexate, azathioprine, and mycophenolate mofetil could be indicated. 37 Immunobiologicals, such as rituximab, are also alternative options for resistant cases, although it has been documented that DH is triggered by infliximab.
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-Follow-up
Once the disease is controlled, with good tolerance to medication, the patient can be monitored every 6 months with clinical and laboratory tests. After the medication is withdrawn, if possible, evaluations may be performed annually. Adherence to diet and the possible development of malabsorption, dyslipidemia, and other CD-related complications, such as autoimmune diseases and lymphoma, should also be assessed.
EVOLUTION AND PROGNOSIS
Up to 20% of patients who adhere to a gluten-free diet for several years may develop immunotolerance and can return to a normal diet. 40, 41 The remaining patients should keep a gluten-free diet to maintain control of their disease.
As in CD, a recent study has shown that the risk of developing non-Hodgkin lymphoma is increased in DH. 42 However, adherence to diet for more than 5 years seems to protect DH patients against lymphomas. 43 Similarly, another recent study of 476 patients showed that the mortality rate due to lymphoma was significantly reduced after 5 years of a gluten-free diet, in addition to being lower in comparison to the general population. 44 A previous study of 846 patients with dietary adherence showed no increased risk of malignancy and a slightly lower mortality rate in DH. 9 The long-term prognosis of DH patients is excellent, but it appears to be related to strict adherence to a gluten-free diet.
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CONCLUSIONS
Dermatitis herpetiformis is considered a cutaneous manifestation of celiac disease, and it should be approached as a primarily intestinal disease. Therefore, despite the absence of digestive manifestations in the majority of patients, adherence to a gluten-free diet is the only effective measure in controlling persistent inflammation of the intestinal mucosa. On the other hand, dapsone can halt the cutaneous manifestations rapidly and can thus be used until they are definitively controlled by a gluten-free diet. 
INTRODUCTION
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LABD is not related to gluten-sensitive enteropathy, which affects adults and children. In this age group, LABD is also known as chronic bullous disease of childhood.
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EPIDEMIOLOGY LABD is a rare disease in adults and children. 48 Yet, it is the most common autoimmune bullous dermatosis in childhood. 49 Its incidence rates varies in different regions. 50 The lowest incidence is in Bavaria, Germany (0.22/million/year). 51, 52 Disease occurrence appears to be the greatest in developing countries in Africa (Tunisia and Uganda), attributed to the distribution of ages in the population, because most of the inhabitants in these countries are minors. 50 The epidemiological data regarding the distribution of cases with regard to gender vary. There are 2 peaks in incidence: infancy, from six months to six years of age, and adulthood, especially from age 60 years.
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ETIOPATHOGENESIS
It is known that subepidermal blisters are caused by IgA1 autoantibodies against antigens of various molecular weights in the basement membrane zone of the skin and mucosa that is lined with stratified squamous epithelium. 52 As in many other autoimmune diseases, the underlying etiology and pathophysiological mechanism that triggers the autoimmune response remain largely unknown. 48 The multitude and complexity of antigens explain the heterogeneity of this disorder in terms of the ultrastructural location of target antigens and epitopes or antigenic source. 48 The major target antigens are the 120-kDa (LAD-1) and 97-kDa (LABD-97) ectodomains of BP180 (collagen XVII), and there are cases with autoantibodies against collagen VII, BP230, α6β4 integrin, laminin, and other proteins. 46, [53] [54] [55] Circulating IgA antibodies are present in one third to one half of patients. 56 The disease pathophysiology involves several inflammatory pathways, such as the activation of the alternative complement pathway; activation of CD4+ lymphocytes, HLA-DR, and CD30+; cytokine synthesis by keratinocytes, such as IL8 and GM-CSF; and recruitment of polymorphonuclear neutrophils and eosinophils.
IgA fixation in these polymorphonuclear cells, through Fc receptor-not direct binding to its antigen-induces the release of proteolytic enzymes in situ, such as collagenase and elastase, thus causing dermoepidermal delamination (or detachment).
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The disease onset may be spontaneous or drug-induced, with vancomycin being the most frequently described trigger. There are also reports of other drugs that cause LABD, such as amiodarone, non-hormonal anti-inflammatories, acetaminophen, captopril, and antibiotics other than vancomycin, such as ceftriaxone, penicillin, and metronidazole. 46, 48, 59 It is believed that cross-reaction of drugs with hemidesmosome antigens results from greater exposure of these antigens, alteration of their structure, or the formation of haptens. These events promote IgA production against BMZ antigens, triggering a response that is similar to those in cases of idiopathic LABD. 48 There are descriptions of LABD cases that have been induced by sun exposure and gestation. 55, 60 Inflammatory diseases and neoplasias have been associated with LABD. Some cases that are related to inflammatory bowel disease, infection, and systemic lupus erythematosus have been described. 46 However, the significance of these correlations remains unknown. 61 With regard to neoplasms, lymphoproliferative diseases (non-Hodgkin lymphoma, chronic lymphocytic leukemia) are more frequent, although there are reports of associated solid neoplasms (eg, bladder, thyroid, and esophagus).
46,48
CLINICAL CONDITION
Cutaneous manifestations are heterogeneous and can mimic other bullous diseases. There may be erythematous papules, urticarial plaques, or vesiculobullous lesions, 46 that may be accompanied by pruritus of variable intensity. The latter are generally tense and may have an annular or arcuate configuration or rosette pattern or bead-like appearance when new bullous lesions arise at the periphery of previous lesions. 46, 62, 63 This clinical characteristic occurs more frequently in children than in adults. 64 The disease can affect the flexor surfaces of limbs and chest, as in bullous pemphigoid, or the extensor regions of the limbs, as in dermatitis herpetiformis. 46, 62 Urticated papules, similar to urticaria, and excoriated papulonodular lesions may also be seen, such as in prurigo. 63, 65 In children, the lesions are located primarily on the lower abdomen and perineal area, with significant involvement of the anogenital area. The face, hands, and feet may also be affected. In adults, the lesions arise mainly on the extensor surfaces, chest, gluteal region, and face (commonly, the perioral area). 48 Mucosal involvement occurs in most cases (60-80%). 46 Any mucous membrane may be affected-most frequently the oral and ocular mucosa. Oral lesions consist of erosions and painful ulcerations, desquamative gingivitis, and cicatricial lesions. 48 Chronic conjunctivitis can lead to symblepharon and even blindness. Drug-induced LABD usually has a more severe, extensive, and atypical presentation than spontaneous disease. 59 There are cases of vancomycin-induced LABD that mimics toxic epidermal necrolysis. 67 The main differential diagnoses in LABD are dermatitis herpetiformis, bullous pemphigoid, mucous membrane pemphigoid, inherited and epidermolysis bullosa acquisita, bullous lupus erythematosus, bullous impetigo, and erythema multiforme. 48, 64 lineAr igA Bullous dermAtosis t
LABORATORY DIAGNOSIS
The pathological examination reveals the presence of subepidermal blisters with a predominantly neutrophilic infiltrate and eventually eosinophils and mononuclear cells. Microabscesses in the dermal papillae may develop. 46 In view of these histopathological findings, common to other bullous dermatoses, DIF must be performed, which yields linear and homogeneous deposits of IgA in the BMZ. Occasionally, IgG, IgM, and C3 are found. [68] [69] [70] Indirect immunofluorescence, used to detect circulating antibodies, may be IgA-positive in half of all cases and can be used to rule out other dermatoses. 56, 69 The salt-split technique, in general,
shows fluorescence on the epidermal side of the blister. 69 Dermoepidermal or dermal fluorescence may occur, however, depending on the antigenic target.
71
TREATMENT
In drug-induced cases, suspension of the suspected drug is essential. 72 Topical corticosteroid therapy on the skin or mucous membrane may be very effective for LABD as a single agent in mild disease or as an adjuvant for limiting the systemic therapeutic dosage in more severe disease. 48 The best options for systemic therapy are sulfones (dapsone) and sulfonamides (sulfapyridine or sulfamethoxypyridazine).
As with dermatitis herpetiformis, dapsone is considered the firstline therapy for LABD. Dapsone therapy is best initiated at low dosages (25 mg/day in adults) and then gradually increased according to control of the clinical condition, as determined by the emergence of new lesions. 57 The dosage is 0.5-3 mg/kg/day for children and 25-150 mg/day for adults. 48 The side effects of this medicine include hemolytic anemia (especially in patients with G6PD deficiency), leukopenia, methemoglobinemia, and abnormalities of liver function tests. 48, 57 For this reason, it is recommended that G6PD levels be measured before starting therapy with dapsone. If the patient does not present with enzyme deficiency, initial monitoring with blood counts and liver function tests is performed weekly in the first month of treatment and then monthly in the subsequent 6 months.
It is also suggested that long-term therapy be monitored every 6 months. 48, 57 Mucosal involvement is typically more resistant to treatment with dapsone alone. 72 Sulfonamides, including sulfapyridine and sulfamethoxypyridazine, are alternatives to dapsone use and may be used alone or in combination with dapsone. Both drugs have similar profiles compared with the adverse effects of dapsone. As with dapsone use, the same precautions apply to sulfonamides. 48, 72 In some patients, LABD is not adequately controlled by these medications or dapsone alone, but the combination with corticosteroids and immunosuppressants, or both, such as azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, and topical tacrolimus may be necessary, mainly due to the side effects of dapsone, which limits its daily dose. 48, 57, 62, 72 There are reports of the benefits of colchicine. 73, 74 As seen in bullous pemphigoid, there are some reported cases of therapeutic success with macrolides, such as erythromycin, and with the combination of tetracycline and nicotinamide. 75, 76 There are others antimicrobial agents that can be used, such as trimethoprim-sulfamethoxazole and oxacillin. 48 Because these drugs fail and because some patients develop unwanted side effects, mainly related to the long-term use of corticosteroids and immunosuppressants, relatively new and safe therapeutic strategies, such as intravenous immunoglobulin and immunoadsorption, have been used successfully in recent years. 48 There is a case report that described the use of rituximab. 77 Systemic therapy is required until patients enter complete clinical remission, after which maintenance of the drug dosages should be adjusted according to the clinical evaluation of mucocutaneous lesions. In case of recurrence, systemic therapy should be restarted and continued over weeks or months after the complete disappearance of all lesions.
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EVOLUTION AND PROGNOSIS
The natural course of the disease is characterized by persistent lesions for several years, with remission occurring in many patients. 63, 64 Among children, remission usually takes place before puberty, although there are cases that persist into adulthood. 64 When the disease endures in adolescence, it is usually milder than the initial presentation. 48 In general, the blisters do not leave scars; alterations in pigmentation are more frequent, such as residual hyperchromia and hypochromia. 63, 64 There seems to be no correlation between the severity of the clinical presentation and disease chronicity. 
